Country Trust Bank’s Standard BioTools LAB Stock Holding History

Country Trust Bank’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-7,552	Closed	-$14.6K	–	388
2024 Q3	$14.6K	Buy	+7,552	New	+$14.8K	﹤0.01%	242

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Country Trust Bank's LAB Position: Q4 2024 in Review

Country Trust Bank sold out of Standard BioTools (LAB) in Q4 2024, closing a stake of 7,552 shares — an estimated $14.6K sold.

Country Trust Bank first reported a position in LAB in Q3 2024 and held it in 1 quarter. The position peaked at $14.6K in Q3 2024. 142 funds tracked by Wall St. Rank hold LAB as of Q4 2024.

Country Trust Bank reported no remaining Standard BioTools position as of Q4 2024 after selling out during the quarter.
Country Trust Bank sold 7,552 Standard BioTools shares in Q4 2024, an estimated $14.6K.
Country Trust Bank first reported a position in Standard BioTools in Q3 2024 and held it in 1 quarter.
Country Trust Bank's Standard BioTools position peaked at $14.6K in Q3 2024.
142 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2024.

Based on Country Trust Bank's 13F filing for Q4 2024, filed 23 Jan 2025.